The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: The updated final trial protocol and rationale of post-initiation trial modifications

Andrea K Viecelli, Elaine Pascoe, Kevan Polkinghorne, Carmel Hawley, Peta Paul-Brent, Sunil Badve, Alan Cass, Stephane Heritier, Peter Kerr, Trevor Mori, Amanda Robertson, Hooi L Seong, Ashley Irish, FAVOURED study team

Research output: Contribution to journalComment/debate

19 Citations (Scopus)
103 Downloads (Pure)


Background: The FAVOURED study is an international multicentre, double-blind, placebo-controlled trial which commenced recruitment in 2008 and examines whether omega-3 polyunsaturated fatty acids (omega-3 PUFAs) either alone or in combination with aspirin will effectively reduce primary access failure of de novo arteriovenous fistulae (AVF) in patients with stage 4 and 5 chronic kidney disease. Publication of new evidence derived from additional studies of clopidogrel and a high screen failure rate due to prevalent aspirin usage prompted an updated trial design. 

Methods/design: The original trial protocol published in 2009 has undergone two major amendments, which were implemented in 2011. Firstly, the primary outcome 'early thrombosis' at 3 months following AVF creation was broadened to a more clinically relevant outcome of 'AVF access failure'; a composite of thrombosis, AVF abandonment and cannulation failure at 12 months. Secondly, participants unable to cease using aspirin were allowed to be enrolled and randomised to omega-3 PUFAs or placebo. The revised primary aim of the FAVOURED study is to test the hypothesis that omega-3 PUFAs will reduce rates of AVF access failure within 12 months following AVF surgery. The secondary aims are to examine the effect of omega-3 PUFAs and aspirin on the individual components of the primary end-point, to examine the safety of study interventions and assess central venous catheter requirement as a result of access failure. 

Discussion: This multicentre international clinical trial was amended to address the clinically relevant question of whether the usability of de novo AVF at 12 months can be improved by the early use of omega-3 PUFAs and to a lesser extent aspirin. This study protocol amendment was made in response to a large trial demonstrating that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. Secondly, including patients taking aspirin will enrol a more representative cohort of haemodialysis patients, who are significantly older with a higher prevalence of cardiovascular disease and diabetes which may increase event rates and the power of the study. 

Original languageEnglish
Article number89
Pages (from-to)1-8
Number of pages8
JournalBMC Nephrology
Publication statusPublished - 27 Jun 2015

Bibliographical note

The study is funded by a National Health and Medical Research Council (NHMRC) Project Grant and registered with the Australian & New Zealand Clinical Trials Register (ACTRN12607000569404).


Dive into the research topics of 'The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: The updated final trial protocol and rationale of post-initiation trial modifications'. Together they form a unique fingerprint.

Cite this